Eugit Therapeutics (Founding)

Funding Details
Awarder
YCombinator
Date Award
July 01, 2022
Vertical
Healthcare,Therapeutics
Funding URL
View Funding Page
Valuation
$0

Company Info
Founding Year
2022
Company Description
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22).
Market
Healthcare
Coinvestors
YCombinator

Links
Back to Home Back to Healthcare,Therapeutics Deals View Funding Announcement